Patents by Inventor Carmel Horgan

Carmel Horgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of screening for inhibitors of osteopontin
    Patent number: 7662633
    Abstract: Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: February 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook
  • Method of screening for inhibitors of osteopontin
    Patent number: 7504232
    Abstract: Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: March 17, 2009
    Assignee: Smithkline Beecham Corporation
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook
  • Method of screening for inhibitors of osteopontin
    Publication number: 20060292648
    Abstract: Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with ?4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
    Type: Application
    Filed: June 22, 2006
    Publication date: December 28, 2006
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook
  • Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin ??and medical use thereof
    Patent number: 7037666
    Abstract: A method for the identification of a modulator of the interaction between latency asssociated peptide (LAP) of transforming growth factor ?1 (TGF-?1) and the integrin avb3, which method comprises: (a) providing, as a first component, LAP-?1 or a functional variant thereof (b) providing, as a second component, integrin avb3 or a functional variant thereof (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-?1 and integrin avb3.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: May 2, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook, David Miller
  • Assay
    Publication number: 20050063969
    Abstract: A method for the identification of a modular of the interaction between latency associated peptide (LAP) of transforming growth factor ?3 (TGF-?3) and ?v integrin, which method comprises: (a) providing, as a first component, LAP-?3 or a functional variant thereof; (b) providing, as a second component, and ?v integrin or a functional variant thereof; (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-?3 and the integrin.
    Type: Application
    Filed: March 14, 2002
    Publication date: March 24, 2005
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook, David Miller
  • Method of screening for inhibitors of osteopontin
    Publication number: 20030186325
    Abstract: Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with &agr;4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
    Type: Application
    Filed: March 17, 2003
    Publication date: October 2, 2003
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook
  • Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
    Publication number: 20030176315
    Abstract: A method for the identification of a modulator of the interaction between latency associated peptide (LAP) of transforming growth factor &bgr;1 (TGF-&bgr;1) and the integrin avb3, which method comprises: (a) providing, as a first component, LAP-&bgr;1 or a functional variant thereof; (b) providing, as a second component, integrin avb3 or a functional variant thereof; (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-&bgr;1 and integrin avb3.
    Type: Application
    Filed: May 5, 2003
    Publication date: September 18, 2003
    Inventors: Simon Barry, Carmel Horgan, Steven Ludbrook, David Miller